ERBB2 and breast carcinoma: With the knowledge that the treatment landscape for breast cancer is changing rapidly [41], it will be of important clinical significance to use such integrative analyses to distinguish between resistant tumors primarily driven by ERBB2 aberrations and those driven by downstream pathways.